


PHARMACEUTICAL 2022

Viking Therapeutics Inc. Rank 147 of 475





PHARMACEUTICAL 2022

Viking Therapeutics Inc. Rank 147 of 475

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 248% points. The greatest weakness of Viking Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is -2.0%, being 274% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	210,528
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,778
Liabilities, Non-Current	0
Other Assets	134
Other Compr. Net Income	-495
Other Expenses	0
Other Liabilities	0
Other Net Income	692
Property and Equipment	0
Research and Development	44,981
Revenues	0
Selling, General and Administrative Expense	10,701

Output Variable	Value in 1000 USD
Assets	210,662
Liabilities	8,778
Expenses	55,682
Stockholders Equity	201,884
Net Income	-54,990
Comprehensive Net Income	-55,238
Economic Capital Ratio	-2.0%